Phase 1, Open-Label Positron Emission Tomography (PET) Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 in Adult Male Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2017
At a glance
- Drugs ATI 9242 (Primary) ; Fallypride 18F
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Braeburn Pharmaceuticals
- 13 Jul 2017 Status changed from active, no longer recruiting to completed.
- 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Jul 2016 New trial record